Randomized phase II trial of bevacizumab (IND# 7921, Avastin) and temsirolimus (IND# 61010, Torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT01222715?term=ARST0921&rank=1

2. Intervention

   Bevacizumab

3. Intervention

   Temsirolimus

4. Intervention

   Avastin

5. Intervention

   Torisel

6. Intervention

   Vinorelbine ditartrate - cyclophosphamide

7. Additional Topic(s)

   Antineoplastic combined chemotherapy

8. Resource Description

   Vinorelbine ditartrate and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread or carry tumor-killing substances to them. Bevacizumab may also stop the growth of rhabdomyosarcoma by blocking blood flow to the tumor. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective when given together with bevacizumab or temsirolimus in treating rhabdomyosarcoma.

9. Contact

   Berenberg, Jeffrey

10. PI

    Wilkinson, Robert, M.D.

11. Topic

    rhabdomyosarcoma

12. Study Population

    Males and females up to 29 years with a previous histological verification of rhabdomyosarcoma at original diagnosis.

13. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=687113&version=healthprofessional

14. Funded by

    Children's Oncology Group

15. Phase

    Phase 2 clinical trial

16. Performed by

    Clinical Protocol & Data Management Shared Resource